Skip to main content
Top
Published in: Endocrine 1/2015

01-02-2015 | Original Article

Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk

Authors: Altan Onat, Mesut Aydın, Günay Can, Etem Çelik, Servet Altay, Ahmet Karagöz, Evin Ademoğlu

Published in: Endocrine | Issue 1/2015

Login to get access

Abstract

Whether euthyroid status affects cardiovascular disease risk is unclear. We aimed to investigate whether serum thyroid-stimulating hormone (TSH) levels within the normal range are related to the risk of coronary heart disease (CHD). In participants of the Turkish Adult Risk Factor Study (mean age 52.7 ± 11.5), in whom TSH was measured in the 2004/05 survey, cross-sectional and longitudinal analyses were performed. Subjects with TSH concentrations <0.3 and >4.2 mIU/L were excluded to ensure euthyroid status leaving 956 individuals as the study sample. Mean follow-up was 4.81 ± 1.3 years. Men had 18 % lower (p < 0.001) geometric mean TSH levels (1.10 mIU/L) than women (1.35 mIU/L). Correlations of TSH with risk variables were notably virtually absent except weakly positive ones in men with age and systolic blood pressure (SBP). The age-adjusted TSH mid-tertile in men was associated with lowest lipoprotein [Lp](a), apoB, and total cholesterol values. Incident CHD was predicted in Cox regression analyses in men [HR of 2.45 (95 %CI 1.05; 5.74] and in combined sexes by the lowest compared with the highest TSH tertile, after adjustment for age, smoking status, SBP, and LDL-cholesterol. Analysis for combined prevalent and incident CHD stratified by metabolic syndrome (MetS) confirmed the independent association with the lowest TSH tertile in men, specifically in men without MetS. TSH levels within normal range, low due to partial assay failure, may manifest as independent predictors of incident CHD, particularly in middle-aged men. Autoimmune responses involving serum Lp(a) under oxidative stress might be implicated mechanistically.
Literature
1.
go back to reference J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn, Prediction of all-cause and cardiovascular mortality in the elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358, 861–865 (2001)CrossRefPubMed J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn, Prediction of all-cause and cardiovascular mortality in the elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358, 861–865 (2001)CrossRefPubMed
2.
go back to reference B.O. Åsvold, T. Bjoro, T.I. Nilsen, L.J. Vatten, Association between blood pressure and serum TSH concentration within the reference range: a population-based study. J. Clin. Endocrinol. Metab. 92, 841–885 (2007)CrossRefPubMed B.O. Åsvold, T. Bjoro, T.I. Nilsen, L.J. Vatten, Association between blood pressure and serum TSH concentration within the reference range: a population-based study. J. Clin. Endocrinol. Metab. 92, 841–885 (2007)CrossRefPubMed
3.
go back to reference B.O. Åsvold, L.J. Vatten, T.I. Nilsen, T. Bjøro, The association between TSH within the reference range and serum lipid concentrations in a population-based study: the HUNT Study. Eur. J. Endocrinol. 156, 181–186 (2007)CrossRefPubMed B.O. Åsvold, L.J. Vatten, T.I. Nilsen, T. Bjøro, The association between TSH within the reference range and serum lipid concentrations in a population-based study: the HUNT Study. Eur. J. Endocrinol. 156, 181–186 (2007)CrossRefPubMed
4.
go back to reference B.O. Åsvold, T. Bjøro, T.I. Nilsen, D. Gunnell, L.J. Vatten, Thyrotropin levels and risk of fatal coronary heart disease. Arch. Intern. Med. 168, 855–860 (2008)CrossRefPubMed B.O. Åsvold, T. Bjøro, T.I. Nilsen, D. Gunnell, L.J. Vatten, Thyrotropin levels and risk of fatal coronary heart disease. Arch. Intern. Med. 168, 855–860 (2008)CrossRefPubMed
5.
go back to reference C.H. Jung, E.J. Rhee, H.S. Shin, S.K. Jo, J.C. Won, C.Y. Park et al., Higher serum free thyroxine levels are associated with coronary artery disease. Endocr. J. 55, 819–826 (2008)CrossRefPubMed C.H. Jung, E.J. Rhee, H.S. Shin, S.K. Jo, J.C. Won, C.Y. Park et al., Higher serum free thyroxine levels are associated with coronary artery disease. Endocr. J. 55, 819–826 (2008)CrossRefPubMed
6.
go back to reference W. Huang, J. Xu, F. Jing, W.B. Chen, L. Gao, H.T. Yuan, J.J. Zhao, Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion. Endocrine Sep 26 (2013) PMID:24065308 [Epub ahead of print] W. Huang, J. Xu, F. Jing, W.B. Chen, L. Gao, H.T. Yuan, J.J. Zhao, Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion. Endocrine Sep 26 (2013) PMID:24065308 [Epub ahead of print]
7.
go back to reference D.S. McLeod, Autoimmune thyroid disease: a novel risk factor for atherosclerosis? Endocrine 44, 8–10 (2013)CrossRefPubMed D.S. McLeod, Autoimmune thyroid disease: a novel risk factor for atherosclerosis? Endocrine 44, 8–10 (2013)CrossRefPubMed
8.
go back to reference O. Topaloglu, F. Gokay, K. Kucukler, F.S. Burnik, T. Mete, H.C. Yavuz et al., Is autoimmune thyroiditis a risk factor for early atherosclerosis in premenopausal women even in euthyroid status? Endocrine 44, 145–151 (2013)CrossRefPubMed O. Topaloglu, F. Gokay, K. Kucukler, F.S. Burnik, T. Mete, H.C. Yavuz et al., Is autoimmune thyroiditis a risk factor for early atherosclerosis in premenopausal women even in euthyroid status? Endocrine 44, 145–151 (2013)CrossRefPubMed
9.
go back to reference A. Onat, G. Can, E. Ayhan, Z. Kaya, G. Hergenç, Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58, 1393–1399 (2009)CrossRefPubMed A. Onat, G. Can, E. Ayhan, Z. Kaya, G. Hergenç, Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58, 1393–1399 (2009)CrossRefPubMed
10.
go back to reference A. Onat, G. Hergenç, Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60, 499–512 (2011)CrossRefPubMed A. Onat, G. Hergenç, Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60, 499–512 (2011)CrossRefPubMed
11.
go back to reference A. Onat, K. Ceyhan, Ö. Başar, B. Erer, S. Toprak, V. Sansoy, Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165, 285–292 (2002)CrossRefPubMed A. Onat, K. Ceyhan, Ö. Başar, B. Erer, S. Toprak, V. Sansoy, Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis 165, 285–292 (2002)CrossRefPubMed
12.
go back to reference A. Onat, G. Hergenç, S. Bulur, M. Uğur, Z. Küçükdurmaz, G. Can, The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int. J. Cardiol. 142, 72–79 (2010)CrossRefPubMed A. Onat, G. Hergenç, S. Bulur, M. Uğur, Z. Küçükdurmaz, G. Can, The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int. J. Cardiol. 142, 72–79 (2010)CrossRefPubMed
13.
go back to reference A. Onat, G. Can, S. Murat, G. Çiçek, E. Örnek, H. Yüksel, Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol. Derg. 13, 543–551 (2013)PubMed A. Onat, G. Can, S. Murat, G. Çiçek, E. Örnek, H. Yüksel, Aggregation of lipoprotein(a) to apolipoprotein A-I underlying HDL dysfunction as a major coronary risk factor. Anadolu Kardiyol. Derg. 13, 543–551 (2013)PubMed
14.
go back to reference A. Onat, G. Can, E. Ademoğlu, E. Çelik, A. Karagöz, E. Örnek, Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J. Investig. Med. 61, 27–33 (2013)PubMed A. Onat, G. Can, E. Ademoğlu, E. Çelik, A. Karagöz, E. Örnek, Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J. Investig. Med. 61, 27–33 (2013)PubMed
15.
go back to reference A. Onat, H. Yüksel, G. Can, B. Köroğlu, A. Kaya, S. Altay, Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. Scand. J. Clin. Lab. Investig. 73, 569–575 (2013)CrossRef A. Onat, H. Yüksel, G. Can, B. Köroğlu, A. Kaya, S. Altay, Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. Scand. J. Clin. Lab. Investig. 73, 569–575 (2013)CrossRef
16.
go back to reference A. Onat, B. Köroğlu, G. Can, A. Karagöz, E. Çelik, M. Aydın, Apparently “low” serum asymmetric dimethylarginine is associated with fasting glucose and tends toward association with type-2 diabetes. Anadolu Kardiyol. Derg. 14(1), 26–33 (2013). doi:10.5152/akd.2013.5009 PubMed A. Onat, B. Köroğlu, G. Can, A. Karagöz, E. Çelik, M. Aydın, Apparently “low” serum asymmetric dimethylarginine is associated with fasting glucose and tends toward association with type-2 diabetes. Anadolu Kardiyol. Derg. 14(1), 26–33 (2013). doi:10.​5152/​akd.​2013.​5009 PubMed
17.
go back to reference A. Onat, G. Can, Enhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharma Design Apr 2 (2013) [Epub ahead of print] A. Onat, G. Can, Enhanced pro-inflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharma Design Apr 2 (2013) [Epub ahead of print]
18.
19.
go back to reference S.M. Grundy, H.B. Brewer, J.I. Cleeman, S.C. Smith Jr, C. Lenfant, American Heart Association; definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004)CrossRefPubMed S.M. Grundy, H.B. Brewer, J.I. Cleeman, S.C. Smith Jr, C. Lenfant, American Heart Association; definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433–438 (2004)CrossRefPubMed
20.
go back to reference A. Onat, H. Uyarel, G. Hergenç, A. Karabulut, S. Albayrak, G. Can, Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191, 182–190 (2007)CrossRefPubMed A. Onat, H. Uyarel, G. Hergenç, A. Karabulut, S. Albayrak, G. Can, Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191, 182–190 (2007)CrossRefPubMed
21.
go back to reference G.A. Rose, H. Blackburn, R.F. Gillum, R.J. Prineas, Cardiovascular Survey Methods, 2nd edn. (WHO, Geneva, 1982), pp. 124–127 G.A. Rose, H. Blackburn, R.F. Gillum, R.J. Prineas, Cardiovascular Survey Methods, 2nd edn. (WHO, Geneva, 1982), pp. 124–127
22.
go back to reference B. Gencer, T.H. Colleo, V. Virgini, D.C. Bauer, J. Gussekloo, A.R. Cappola et al., Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 172, 799–809 (2012)PubMed B. Gencer, T.H. Colleo, V. Virgini, D.C. Bauer, J. Gussekloo, A.R. Cappola et al., Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 172, 799–809 (2012)PubMed
23.
go back to reference S. Tognini, A. Polini, G. Pasqualetti, S. Ursino, N. Caraccio, M. Ferdeghini et al., Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study. Thyroid 22, 1096–1103 (2012)CrossRefPubMed S. Tognini, A. Polini, G. Pasqualetti, S. Ursino, N. Caraccio, M. Ferdeghini et al., Age and gender substantially influence the relationship between thyroid status and the lipoprotein profile: results from a large cross-sectional study. Thyroid 22, 1096–1103 (2012)CrossRefPubMed
24.
go back to reference M. Rotondi, P. Leporati, M.I. Rizza, A. Clerici, G. Groppelli, C. Pallavicini et al., Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile. Endocrine 43, 230–232 (2013)CrossRef M. Rotondi, P. Leporati, M.I. Rizza, A. Clerici, G. Groppelli, C. Pallavicini et al., Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile. Endocrine 43, 230–232 (2013)CrossRef
25.
go back to reference L. Siemińska, W. Foltyn, J. Głogowska-Szeląg, D. Kajdaniuk, B. Marek, M. Nowak et al., Relationships between adiponectin, sex hormone binding globulin and insulin resistance in hyperthyroid Graves’ disease women. Endokrynol. Pol 64, 26–29 (2013)PubMed L. Siemińska, W. Foltyn, J. Głogowska-Szeląg, D. Kajdaniuk, B. Marek, M. Nowak et al., Relationships between adiponectin, sex hormone binding globulin and insulin resistance in hyperthyroid Graves’ disease women. Endokrynol. Pol 64, 26–29 (2013)PubMed
26.
go back to reference C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach et al., Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249–1252 (1994)CrossRefPubMed C.T. Sawin, A. Geller, P.A. Wolf, A.J. Belanger, E. Baker, P. Bacharach et al., Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331, 1249–1252 (1994)CrossRefPubMed
27.
go back to reference J. Gussekloo, E. van Exel, A.J. de Craen, A.E. Meinders, M. Frölich, R.G. Westendorp, Thyroid status, disability and cognitive function, and survival in old age. J. Am. Med. Assoc. 292, 2591–2599 (2004)CrossRef J. Gussekloo, E. van Exel, A.J. de Craen, A.E. Meinders, M. Frölich, R.G. Westendorp, Thyroid status, disability and cognitive function, and survival in old age. J. Am. Med. Assoc. 292, 2591–2599 (2004)CrossRef
28.
go back to reference L.H. Duntas, B. Biondi, Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur. J. Endocrinol. 156, 13–19 (2007)CrossRefPubMed L.H. Duntas, B. Biondi, Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur. J. Endocrinol. 156, 13–19 (2007)CrossRefPubMed
29.
go back to reference A. Dardano, K.L. Ghiadoni, Y. Plantinga, N. Carraccio, A. Bemi, E. Duranti et al., Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 4175–4178 (2006)CrossRefPubMed A. Dardano, K.L. Ghiadoni, Y. Plantinga, N. Carraccio, A. Bemi, E. Duranti et al., Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 4175–4178 (2006)CrossRefPubMed
30.
go back to reference T.T. Antunes, A. Gagnon, A. Bell, A. Sorisky, Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes. Res. 13, 2066–2071 (2005)CrossRefPubMed T.T. Antunes, A. Gagnon, A. Bell, A. Sorisky, Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes. Res. 13, 2066–2071 (2005)CrossRefPubMed
31.
go back to reference H.C. Wang, J. Dragoo, O. Zhou, J.R. Klein, An intrinsic thyrotropin-mediated pathway of TNF-alpha production by bone marrow cells. Blood 101, 119–123 (2003)CrossRefPubMed H.C. Wang, J. Dragoo, O. Zhou, J.R. Klein, An intrinsic thyrotropin-mediated pathway of TNF-alpha production by bone marrow cells. Blood 101, 119–123 (2003)CrossRefPubMed
32.
go back to reference H. Taneichi, T. Sasai, M. Ohara, H. Honma, K. Nagasawa, T. Takahashi, Higher serum free triiodothyronine levels within the normal range are associated with metabolic syndrome components in type 2 diabetic subjects with euthyroidism. Tohoku J. Exp. Med. 224, 173–178 (2011)CrossRefPubMed H. Taneichi, T. Sasai, M. Ohara, H. Honma, K. Nagasawa, T. Takahashi, Higher serum free triiodothyronine levels within the normal range are associated with metabolic syndrome components in type 2 diabetic subjects with euthyroidism. Tohoku J. Exp. Med. 224, 173–178 (2011)CrossRefPubMed
33.
go back to reference Q. Qi, T. Workalemahu, C. Zhang, F.B. Hu, L. Qi, Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular mortlity and mortality among two prospective cohorts of type 2 diabetes. Eur. Heart J. 33, 325–334 (2012)CrossRefPubMedCentralPubMed Q. Qi, T. Workalemahu, C. Zhang, F.B. Hu, L. Qi, Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular mortlity and mortality among two prospective cohorts of type 2 diabetes. Eur. Heart J. 33, 325–334 (2012)CrossRefPubMedCentralPubMed
34.
go back to reference A. Onat, M. Aydın, G. Can, H.A. Çakmak, B. Köroğlu, A. Kaya et al., Impaired fasting glucose: pro-diabetic, “atheroprotective” and modified by metabolic syndrome. World. J. Diabetes 4, 210–218 (2013)PubMedCentralPubMed A. Onat, M. Aydın, G. Can, H.A. Çakmak, B. Köroğlu, A. Kaya et al., Impaired fasting glucose: pro-diabetic, “atheroprotective” and modified by metabolic syndrome. World. J. Diabetes 4, 210–218 (2013)PubMedCentralPubMed
35.
go back to reference S. Mora, P.R. Kamstrup, N. Rifai, B.G. Nordestgaard, J.E. Buring, P.M. Ridker, Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56, 1252–1260 (2010)CrossRefPubMedCentralPubMed S. Mora, P.R. Kamstrup, N. Rifai, B.G. Nordestgaard, J.E. Buring, P.M. Ridker, Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56, 1252–1260 (2010)CrossRefPubMedCentralPubMed
36.
go back to reference A. Onat, H.A. Çakmak, G. Can, M. Yüksel, B. Köroğlu, H. Yüksel, Serum total and high-density lipoprotein phospholipids: Independent predictive value for cardiometabolic risk. Clin Nutr. Nov 1 (2013) [Epub ahead of print] A. Onat, H.A. Çakmak, G. Can, M. Yüksel, B. Köroğlu, H. Yüksel, Serum total and high-density lipoprotein phospholipids: Independent predictive value for cardiometabolic risk. Clin Nutr. Nov 1 (2013) [Epub ahead of print]
37.
go back to reference K. Kocak, B. Huddam, A. Azak, L. Ortabozkoyun, M. Duranay, Coexistent findings of renal glomerular disease with Hashimoto’s thyroiditis. Clin. Endocrinol. 76, 759–762 (2012)CrossRef K. Kocak, B. Huddam, A. Azak, L. Ortabozkoyun, M. Duranay, Coexistent findings of renal glomerular disease with Hashimoto’s thyroiditis. Clin. Endocrinol. 76, 759–762 (2012)CrossRef
38.
go back to reference C. Zhang, X. Li, D. Niu, R. Zi, C. Wang, A. Han et al., Increased serum levels of ß2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients with rheumatoid arthritis. Clin. Chim. Acta 412, 1332–1336 (2011)CrossRefPubMed C. Zhang, X. Li, D. Niu, R. Zi, C. Wang, A. Han et al., Increased serum levels of ß2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients with rheumatoid arthritis. Clin. Chim. Acta 412, 1332–1336 (2011)CrossRefPubMed
39.
go back to reference L.R. Lopez, T.R. Bruckner, B.L. Hurley, K. Kobayashin, E. Matsuura, Determination of oxidized low-density lipoprotein (ox-LDL) versus oxLDL/beta2-GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann. N. Y. Acad. Sci. 1109, 303–310 (2007)CrossRefPubMed L.R. Lopez, T.R. Bruckner, B.L. Hurley, K. Kobayashin, E. Matsuura, Determination of oxidized low-density lipoprotein (ox-LDL) versus oxLDL/beta2-GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann. N. Y. Acad. Sci. 1109, 303–310 (2007)CrossRefPubMed
Metadata
Title
Normal thyroid-stimulating hormone levels, autoimmune activation, and coronary heart disease risk
Authors
Altan Onat
Mesut Aydın
Günay Can
Etem Çelik
Servet Altay
Ahmet Karagöz
Evin Ademoğlu
Publication date
01-02-2015
Publisher
Springer US
Published in
Endocrine / Issue 1/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0269-z

Other articles of this Issue 1/2015

Endocrine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.